Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvie D Freeman

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Haematologica|March 17, 2022
Delving the depths of measurable residual disease negativity in acute myeloid leukemiaSylvie D Freeman
Transplantation and Cellular Therapy|June 19, 2021
Selection of Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplasia - New Evidence EmergesSylvie D Freeman, Charles Craddock
Blood|June 16, 2022
Transplant in older adults with AML: genomic wheat and chaffSylvie D Freeman, Peter Valk
Blood|July 23, 2014
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?David Grimwade, Sylvie D Freeman
Hematology. American Society of Hematology. Education Program|February 20, 2015
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?David Grimwade, Sylvie D Freeman
Hematology. American Society of Hematology. Education Program|December 7, 2019
MRD evaluation of AML in clinical practice: are we there yet?Sylvie D Freeman, Christopher S Hourigan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2021
Reply to G. Gui et alCharles Craddock, Aimee Jackson, Sylvie D Freeman
Blood Advances|June 14, 2018
Evaluating measurable residual disease in acute myeloid leukemiaFarhad Ravandi, Roland B Walter, Sylvie D Freeman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2025
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AMLNigel H Russell, Abin Thomas, Sylvie D Freeman
Seminars in Oncology|August 12, 2008
Development of minimal residual disease-directed therapy in acute myeloid leukemiaSylvie D Freeman, Jelena V Jovanovic, David Grimwade
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Haematologica|March 17, 2022
Delving the depths of measurable residual disease negativity in acute myeloid leukemiaSylvie D Freeman
Transplantation and Cellular Therapy|June 19, 2021
Selection of Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplasia - New Evidence EmergesSylvie D Freeman, Charles Craddock
Blood|June 16, 2022
Transplant in older adults with AML: genomic wheat and chaffSylvie D Freeman, Peter Valk
Blood|July 23, 2014
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?David Grimwade, Sylvie D Freeman
Hematology. American Society of Hematology. Education Program|February 20, 2015
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?David Grimwade, Sylvie D Freeman
Hematology. American Society of Hematology. Education Program|December 7, 2019
MRD evaluation of AML in clinical practice: are we there yet?Sylvie D Freeman, Christopher S Hourigan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2021
Reply to G. Gui et alCharles Craddock, Aimee Jackson, Sylvie D Freeman
Blood Advances|June 14, 2018
Evaluating measurable residual disease in acute myeloid leukemiaFarhad Ravandi, Roland B Walter, Sylvie D Freeman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2025
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AMLNigel H Russell, Abin Thomas, Sylvie D Freeman
Seminars in Oncology|August 12, 2008
Development of minimal residual disease-directed therapy in acute myeloid leukemiaSylvie D Freeman, Jelena V Jovanovic, David Grimwade
Pageof 6